Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Conditions

• Malignant Neoplasms
• Von Hippel-Lindau Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Belzutifan — DRUG
  Belzutifan is administered orally at 120 mg once daily (qd) OR 200 mg qd until progressive disease (PD), unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
• Nivolumab — DRUG
  Nivolumab is administered intravenously at 480 mg until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
• Lenvatinib — DRUG
  Lenvatinib is administered orally at 20 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
• Cabozantinib — DRUG
  Cabozantinib is administered orally at 60 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.

Study Details

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.

Key Dates

First listed

Feb 12, 2026

Start date

Mar 23, 2026

Status verified

Jul 2026

Primary completion

Jan 14, 2034

Completion

Jan 14, 2034

Study Design

Enrollment

450 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Cohort A: Belzutifan Monotherapy
  Participants on active treatment assigned to belzutifan monotherapy in a parent study are transitioned to this extension study. Participants will continue the same dose and frequency of intervention as they were receiving in the parent study at the time of the transition. Treatment will continue until progressive disease (PD), unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
• Experimental: Cohort B: Belzutifan Combination Therapy
  Participants on active treatment assigned to a belzutifan combination therapy in a parent study are transitioned to this extension study. Participants will continue the same dose and frequency of intervention as they were receiving in the parent study at the time of the transition. Treatment will continue until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
• Active Comparator: Cohort C: Non-Belzutifan Therapy
  Participants on active treatment assigned to a non-belzutifan therapy in a parent study are transitioned to this extension study. Participants will continue the same dose and frequency of intervention as they were receiving in the parent study at the time of the transition. Treatment will continue until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.

Primary Outcome Measure

Cohort A and Cohort B: Overall Survival (OS) [ Time Frame: Up to approximately 7 years ]

Central Contacts

• Toll Free Number
  1-888-577-8839
  [email protected]

Locations (7)

Find similar trials in Boston, MA

Related Studies

• Familial Investigations of Childhood Cancer Predisposition
  Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
• MyVHL: Patient Natural History Study
  Recruiting · Joshua Mann, MPH · Boston, Massachusetts
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
  PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Los Angeles, California
• A Multi Center Study of Sexual Toxicities After Radiotherapy
  Recruiting · Icahn School of Medicine at Mount Sinai · Atlanta, Georgia